Propranolol for infantile hemangioma: An evaluation of its efficacy and safety in Iranian infants

Authors

  • Ali Taherian MD, Assistant of Pathology, Department of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran
  • Behzad Alizadeh MD, Assistant Professor of Pediatric Cardiac Diseases, Department of Cardiac Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
  • Fatemeh Livani MD, Assistant Professor of Dermatology, Golestan University of Medical Sciences, Gorgan, Iran
  • Maryam Amin Moghaddam MD, , Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  • Mohammad Abbasi Tashnizi MD, Associate Professor of Pediatric Cardiac Diseases, Department of Cardiac Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
  • Pouran Layegh MD, Professor of Dermatology, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:

Background: Propranolol has been recently indicated to inhibit the rapid growth and involution of infantile hemangioma. In the present study, we investigated the efficacy and safety of propranolol in Iranian infants. Methods: A total of 30 infants with indications for medical intervention, such as large hemangiomas, wounds with or without secondary infection, or active trauma-induced bleeding, were selected. First, a total concentration of 1 mg/kg/day was orally administered to the infants; the dosage further increased (2-3 mg/kg/day) in case the infants experienced no adverse effects. Following weekly (one month after treatment) and monthly (up to six months) follow-ups, hemangioma activity score (HAS) was calculated to evaluate swelling, color of the lesion, and ulcer size. Results: In the present study, infants with the mean age of 5.33±3.50 years received therapy. Improvement was observed in the lesions of all patients, characterized by a significant decline in size, change in color, and reduction in ulcer size (P

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

propranolol for infantile hemangioma: an evaluation of its efficacy and safety in iranian infants

background: propranolol has been recently indicated to inhibit the rapid growth and involution of infantile hemangioma. in the present study, we investigated the efficacy and safety of propranolol in iranian infants. methods: a total of 30 infants with indications for medical intervention, such as large hemangiomas, wounds with or without secondary infection, or active trauma-induced bleeding, ...

full text

Propranolol therapy for infantile hemangioma.

CONTEXT There has been widespread interest surrounding the use of beta-blockers (i.e. propranolol, timolol, nadolol, acebutolol) in the treatment of infantile hemangiomas (IH). OBJECTIVE To review literature evaluating treatment of IH with propranolol. EVIDENCE ACQUISITION We conducted a literature search on PubMed and investigated for case reports, case series, and controlled trials by usi...

full text

an investigation into iranian teachers consistency and bias in evaluation of students writings

while performance-based language assessment has led to an increased authenticity and content validity in the practice of writing assessment, the reliability of ratings has become a major issue. research findings have shown different reactions by native english speaker (nes) and non-native english speaker (nns) teachers to students’ writings. the focus of this study is on investigating whether i...

Propranolol therapy for infantile hemangioma: our experience

OBJECTIVE Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of I...

full text

Mechanisms of propranolol action in infantile hemangioma

Infantile hemangioma is a common tumor of infancy. Although most hemangiomas spontaneously regress, treatment is indicated based on complications, risk to organ development and function, and disfigurement. The serendipitous discovery of propranolol, a non-selective β-adrenergic receptor blocker, as an effective means to regress hemangiomas has made this a first-line therapy for hemangioma patie...

full text

When to stop propranolol for infantile hemangioma

There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH). A total of 149 patients who underwent detailed color Doppler ultrasound examination were included in this study. The characteristics and propranolol treatment of all patients were summarized and analyzed. Patients were divided into two groups according to the lesio...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 3

pages  17- 20

publication date 2016-10-01

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023